CTOs on the Move

Glycomine

www.glycomine.com

 
There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Glycomine raised $33M on 08/07/2019

Similar Companies

Orphan Star Therapeutics

Orphan Star Therapeutics, LLC, a biopharmaceutical company, develops therapies for rare genetic diseases including Canavan disease, glut1 deficiency, and rare genetic skin diseases.

Q-State Biosciences

Q-State Biosciences is a technology-derived medicines company based in Cambridge, MA, that combines advanced human cellular models, unique measurement engineering and AI / machine learning into a proprietary platform that enables novel discovery of optimized genetically targeted medicines for epilepsy, pain, and other diseases of the CNS.

MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients. In addition, MannKind is applying our novel technologies and services to support partner development efforts.

Relay Technology Management

Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.

CINDE Journal

CINDE Journal is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.